JAK2V617F在原发性血小板增多症的表达情况与临床特征分析  

Analysis of JAK2 V617 F Expression and Clinical Features in Essential Thrombocythemia

作　　者：孙兴卫[1] SUN Xingwei(Department of Hematology and Oncology,Zhengzhou Second People's Hospital,Zhengzhou Henan 450000,China)

机构地区：[1]郑州市第二人民医院肿瘤血液科,河南郑州450000

出　　处：《临床研究》2025年第2期88-91,共4页Clinical Research

摘　　要：目的通过对原发性血小板增多症(ET)患者进行JAK2 V617 F突变的检测,研究JAK2 V617 F突变对于ET患者的临床特征以及预后的关系,为ET患者诊断治疗提供帮助。方法按照世界卫生组织(WHO)诊断标准,收集2018年4月至2024年2月确诊的82例ET患者,通过收集其外周血血小板数、中性粒细胞数、白细胞数、血红蛋白以及纤维蛋白原含量,利用聚合酶链式反应(PCR)技术检测骨髓或外周血中JAK2 V617 F突变的表达。结果(1)本研究收集的82例ET患者中,存在JAK2 V617 F突变的患者有65例,占所有ET患者的79.27%;(2)在ET患者中,JAK2 V617 F基因的表达与性别无关(P=0.947),但是与年龄相关,>50岁组JAK2 V617 F基因突变占比更高,差异具有统计学意义(P=0.020);(3)存在JAK2 V617 F基因的突变的患者血小板数低于阴性患者,差异具有统计学意义(P=0.017),而中性粒细胞数、白细胞数以及纤维蛋白原的检出量则明显较高,差异均有统计学意义(P<0.001);(4)观察患者预后情况,JAK2 V617 F基因的突变会提升血栓以及脾增大风险,差异均有统计学意义(P<0.05)。结论JAK2V617 F突变对原发性血小板增多症的预后产生较大影响,同时可能参与原发性血小板增多症的发病过程。Objective This study aims to investigate the relationship between JAK2 V617 F mutation and the clinical characteristics and prognosis of patients with essential thrombocythemia(ET)by detecting the JAK2 V617 F mutation in ET patients,thereby providing assistance for the diagnosis and treatment of ET.Methods According to the World Health Organization(WHO)diagnostic criteria,a total of 82 confirmed ET patients from April 2018 to February 2024 were collected.Peripheral blood platelet count,neutrophil count,white blood cell count,hemoglobin,and fibrinogen levels were gathered.The expression of JAK2 V617 F mutation in bone marrow or peripheral blood was detected using polymerase chain reaction(PCR)technology.Results(1)Among the 82 ET patients collected in this study,65 patients were found to have the JAK2 V617 F mutation,accounting for 79.27%of all ET patients;(2)Within ET patients,the expression of the JAK2 V617 F gene was not related to sex(P=0.947),but was related to age,with a higher proportion of JAK2 V617 F mutation in the group aged>50 years,which was statistically significant(P=0.020);(3)Patients with the JAK2 V617 F mutation had lower platelet counts than those who were negative for the mutation,and the difference was statistically significant(P=0.017).Meanwhile,the levels of neutrophils,white blood cells,and fibrinogen were significantly higher,with all differences being statistically significant(P<0.001);(4)Observing patient prognosis,the JAK2 V617 F mutation was associated with an increased risk of thrombosis and splenomegaly,with both differences being statistically significant(P<0.05).Conclusion The JAK2 V617 F mutation has a significant impact on the prognosis of essential thrombocythemia and may participate in the pathogenesis of essential thrombocythemia.

关 键 词：原发性血小板增多症 JAK2V617 F 临床特征 预后 

分 类 号：R558.3[医药卫生—血液循环系统疾病]